Boston Children's Hospital
The investigators propose a robust therapeutic intervention to ameliorate myocardial ischemia/ reperfusion injury and significantly decrease morbidity and mortality in patients requiring extracorporeal membrane oxygenation (ECMO), by direct injection of autogeneic mitochondria into the ischemic myocardium.
Autologous mitochondria will be delivered to the ischemic heart muscle in one of two ways, during clinically indicated surgical procedure or during clinically indicated cardiac catheterization. For surgical re-operation subjects: After the subject's chest is open, 1-2 6mm biopsies will be collected from the exposed skeletal muscle of the chest wall. The tissue will be processed at bedside to extract the autologous mitochondria. Surgery will proceed as clinically indicated. Prior to closure of the chest, autologous mitochondria will be injected via 5-10 injections of approximately 0.1 mL each…
Inclusion Criteria: * Pediatric cardiology patients under the age of 18 on ECMO * concerns for ischemic injury on the Cardiac Intensive Care Unit Exclusion Criteria: * Known mitochondria disorders
Autologous mitochondria obtained from the subject's own skeletal muscle will be injected or infused into the ischemic myocardium
Arctuva estimate
Verify or correct the compensation shown for this listing.